CLVS up +1.40% percent right now. $CLVS High is at 61.25

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 2:48 PM

CLVS up +1.40% percent right now. $CLVS High is at 61.25 and the Low 59.62 with current volume of 219,176.

Recent News posted below.

CLVS Clovis Oncology Inc Recent Headline News

Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:40PM CST

CLVS: 60.40 (+0.26)

Clovis misses 3Q profit forecasts
Automated Insights - Thu Nov 06, 6:39PM CST
BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Thursday reported a loss of $39.6 million in its third quarter.
CLVS: 60.40 (+0.26)

Clovis Oncology misses by $0.10
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:00PM CST

CLVS: 60.40 (+0.26)

Clovis Oncology Announces Third Quarter 2014 Operating Results
Business Wire - Thu Nov 06, 3:01PM CST
--$278.3 million raised in September sale of senior convertible notes
CLVS: 60.40 (+0.26)

Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST

BEBE: 2.45 (+0.07), ACET: 21.11 (-0.30), ANET: 78.59 (+1.80), FNGN: 31.23 (-0.12), CPST: 0.98 (+0.03), AUQ: 3.64 (+0.43), AMRN: 0.82 (-0.01), ED: 63.36 (-0.11), ENV: 54.04 (+1.92), FXCM: 16.52 (-0.06), BCEI: 41.03 (+0.84), GXP: 27.05 (-0.10), EAC: 12.47 (-0.48), DXCM: 52.96 (-0.54), CSC: 59.92 (+0.61), AEL: 27.36 (-0.48), HNSN: 0.69 (-0.06), CFN: 57.49 (-0.03), ANAC: 31.23 (+0.69), DAR: 18.85 (+0.08), GST: 4.15 (+0.13), ARC: 9.99 (-0.18), FIVN: 4.77 (-0.06), ELON: 1.97 (-0.06), FSLR: 50.80 (-1.16), EZPW: 10.96 (-0.03), ALIM: 5.13 (-0.01), FWM: 2.30 (-0.13), BRS: 72.34 (+1.27), ECOM: 18.60 (+0.26), FTEK: 4.01 (-0.04), CVT: 28.39 (-0.12), AL: 37.31 (-0.43), BBRG: 12.94 (+0.32), BPZ: 0.95 (-0.01), ECPG: 45.22 (-0.01), HTGC: 16.11 (+0.01), AIRM: 43.39 (-0.09), BNFT: 26.19 (+0.69), ENOC: 14.99 (-0.06), HPTX: 21.69 (+0.11), AGO: 24.51 (-0.07), FICO: 71.72 (+0.99), FF: 12.59 (-0.46), FI: 19.37 (+0.29), EVC: 5.17 (+0.03), EBS: 24.51 (+0.56), ABCO: 46.97 (-0.49), DIOD: 26.09 (+0.05), DIS: 89.66 (-0.12), EGOV: 17.07 (+0.06), APEI: 35.94 (-0.11), DVA: 75.15 (+0.43), CLVS: 60.40 (+0.26), HCI: 44.12 (+0.21), BRKR: 18.24 (+0.30), HGR: 20.72 (+0.13)

Clovis Oncology to Present at the 2014 Credit Suisse Healthcare Conference
Business Wire - Tue Nov 04, 3:07PM CST
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company's President and CEO, will present at the 2014 Credit Suisse Healthcare Conference on Tuesday, November 11, at 2:00pm MST. The conference is being held at the Arizona Biltmore in Phoenix, Arizona.
CLVS: 60.40 (+0.26)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 108.43 (+1.41), CLVS: 60.40 (+0.26), ARWR: 6.40 (+0.19), ACHN: 12.43 (-0.42), MRK: 59.25 (+0.44), RTRX: 11.05 (+0.31), RGLS: 20.14 (-0.77), EPZM: 24.31 (+0.44), AGIO: 82.20 (+0.42), RMTI: 11.14 (+0.24), ARNA: 4.51 (+0.11), KERX: 15.86 (-0.57)

AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:41PM CDT
The CHMP gave a positive opinion in favour of approving AstraZeneca's (AZN) Lynparza.
AGN: 195.48 (+0.24), CLVS: 60.40 (+0.26), AZN: 74.28 (+1.07), REGN: 398.68 (+12.71)

Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer
Business Wire - Thu Oct 23, 3:52PM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer (NSCLC) has commenced and the first patient has been dosed at a U.S. study site. Lucitanib is the Company's oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a-ss).
CLVS: 60.40 (+0.26)

3 Beaten Down Biotech Stocks to Buy Now
George Budwell, The Motley Fool - Motley Fool - Thu Oct 23, 10:20AM CDT
Biotech stocks that crumble after a clinical or regulatory setback can turn out to be stellar long-term buys. Even so, it's critical to understand why the stock plunged in the first place, and how management plans on putting the company on track to...
DVAX: 16.75 (+0.77), CLVS: 60.40 (+0.26), CLDX: 14.58 (-0.23), AZN: 74.28 (+1.07), GSK: 45.83 (+0.67)

Clovis reports November 6
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:42AM CDT

CLVS: 60.40 (+0.26)

Clovis Oncology to Announce Third Quarter 2014 Financial Results and Host Webcast Conference Call on November 6
Business Wire - Wed Oct 22, 8:01AM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2014 financial results on Thursday, November 6, 2014, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company's results in greater detail.
CLVS: 60.40 (+0.26)

Fallopian Tube Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b25z3h/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - MedImmune, LLC - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - ImmunoGen, Inc. - Astex Pharmaceuticals, Inc. - CTI BioPharma Corp. - Bayer AG - Incyte Corporation - Active Biotech AB - Oncolytics Biotech Inc. - OXiGENE, Inc. - Curis - Topotarget - NeoStem - Pharmacyclics - Synta - Oasmia - MabVax - Acceleron - Cerulean - OncoMed - TetraLogic Pharmaceuticals - Merrimack Pharmaceuticals, Inc. - Immunovaccine, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - Clovis Oncology, Inc. - Recepta Biopharma S.A. - EGEN, Inc. - Sanofi Pasteur SA - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/b2...opian_tube
ONCY: 0.84 (unch), INCY: 71.34 (+0.38), IMGN: 10.24 (+0.29), AMGN: 162.30 (-0.79), LLY: 67.91 (-0.44), CTIC: 2.22 (+0.08), GSK: 45.83 (+0.67), OXGN: 1.91 (-0.07), MACK: 8.49 (-0.21), JNJ: 108.87 (+0.05), CLVS: 60.40 (+0.26), ABBV: 63.59 (-0.20), NVS: 92.63 (unch)

Nasdaq stocks posting largest percentage increases
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
LOXO: 11.78 (-0.15), TRVN: 5.71 (-0.14), UNXL: 5.44 (+0.01), GLBZ: 12.40 (-0.08), EFOI: 6.28 (-0.30), CLVS: 60.40 (+0.26), TIBX: 23.65 (-0.01), AKAO: 10.01 (+0.13), MOVE: 20.97 (-0.02)

Ford and eBay are big market movers
AP - Tue Sep 30, 3:24PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
ATHL: 58.44 (+0.05), F: 14.30 (+0.30), TK: 53.76 (-0.34), BGC: 13.98 (-0.07), MOVE: 20.97 (-0.02), MAS: 23.23 (+0.05), NWSA: 15.29 (+0.05), CTAS: 70.92 (-0.19), EBAY: 54.22 (+0.33), TIBX: 23.65 (-0.01), CLVS: 60.40 (+0.26), CVEO: 10.91 (+0.10), VIMC: 9.27 (-0.08), AMAG: 34.97 (+0.06), NWS: 14.97 (+0.03), TA: 9.28 (-0.09)

Critical Alerts For Yahoo!, Clovis Oncology, Sears Holdings, PetSmart and Endo Health Solutions Released By InvestorsObserver
PR Newswire - Tue Sep 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for YHOO, CLVS, SHLD, PETM and ENDP.
ENDP: 67.43 (-1.44), YHOO: 48.91 (-0.50), CLVS: 60.40 (+0.26), SHLD: 37.26 (-1.46), PETM: 72.29 (-0.45)

Big News for These 5 Stocks From ESMO
Brian Orelli, The Motley Fool - Motley Fool - Tue Sep 30, 8:05AM CDT
The news from the European Society for Medical Oncology meeting, or ESMO, came mostly from the large pharmas -- Roche , Merck , and AstraZeneca in particular -- but a couple of smaller biotechs are benefiting. Shares of Clovis Oncology and ...
CLVS: 60.40 (+0.26), MRK: 59.26 (+0.45), AZN: 74.28 (+1.07), BMY: 58.71 (-0.10), EXEL: 1.79 (unch)

Clovis Oncology (CLVS) Soars: Stock Adds 13.2% is Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 7:51AM CDT
Clovis Oncology, Inc. (CLVS) was a big mover last session, as its shares rose over 13% on the day.
CBM: 23.58 (+0.62), CLVS: 60.40 (+0.26), GILD: 108.43 (+1.41)

3 Unusual-Volume Stocks Triggering Breakout Trades
at The Street - Tue Sep 30, 6:00AM CDT
Keep these stokcs rising on unusual volume on your breakout trading radar.
CLVS: 60.40 (+0.26), CONN: 32.22 (+0.76), IRM: 37.65 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Advenica: Rising Star in Secure File Transfer Market

Advenica's Ascent in Secure File Transfer The cybersecurity world never sleeps, and with the rapid pace of digital threats, it's no surprise that secure file transfer solutions are becoming hotter commodities than coffee pots on Wall Street. Advenica, a name that might not ring a bell for everyone, has emerged as an 'Emerging Leader' in MarketsandMarkets' latest...

KuCoin's KCUSD Tackles Stablecoin Idle Capital Problem

KuCoin's Bold Move with KCUSD Folks, the cat's outta the bag with KuCoin's latest maneuver—introducing KCUSD. At first glance, it seems like they're just introducing another fancy stablecoin product, but peel the onion and there's more to it. We're talking about shaking up how stablecoins sit tight doing nada in the crypto world. KCUSD is out to make those idle balances...

Europe's Largest Carbon Capture Facility Launches

A New Chapter in Industrial Decarbonization Today's not just your average ribbon-cutting ceremony; it's a landmark turn in our journey toward a cleaner Europe. Yara's Sluiskil plant in the Netherlands just fired up Europe's biggest carbon capture facility, marking a crucial pivot point in industrial decarbonization. We're talking about capturing a staggering 800,000 tons...

Sungrow's MGTL Series: A Game-Changer in Solar Tech

Smarter Energy Systems Are Here Gone are the days when solar inverters were just clunky bits of tech you threw on a roof. Sungrow's latest MGTL Series, revealed in Da Nang, marks a revolutionary step for Southeast Asia, Africa, Latin America, and beyond. They're not just talking the talk—they're bringing real innovation to the table. Why the MGTL Series Stands Out Look,...

Snack Bars Market to Hit $32.66B by 2031: Growth and Challenges

Snack Bars Navigate a Transforming Market There's a headwind in the snack bars market as it looks to lift off from $21.94 billion and land at $32.66 billion by 2031. That's a solid climb at an 8.28% CAGR. What's fueling this leap? A desire for convenient, portable nutrition that's squeezing into every nook of modern life—from the gym to the car, to your kid's lunchbox....

Michigan Roof Inspections: Seasonal Insights That Count

Weather's Wrath and the Michigan Roof Here's the deal: Michigan doesn't mess around when it comes to weather. We're talking harsh winters with piles of snow, followed by muggy summers that toss storms like they're confetti. Keeping that roof in top shape isn't just some luxury; it’s a downright necessity. Gut-punch reality? Many ignore it until it's too late. That's...

53% of European Telecom Users Eye Provider Switch

Change Is Brewing in Europe's Telecom Markets Seems like Europe's telco scene is simmering. Over half of consumers in major European markets are giving their mobile providers the side-eye, ready to jump ship. That's putting the heat on operators who once banked on loyalty programs to keep their customer base intact. Diverse Loyalty Challenges Across Europe What's...

Overpricing in Atlanta Luxury Real Estate: Risks & Rewards

When Pricing Sends the Wrong Message Jump into the high stakes poker game of Atlanta's luxury real estate, and you'll find that pricing strategy is your make-or-break move. Jud Whitlock, a seasoned veteran over at Atlanta Fine Homes/Sotheby's International Realty, lays it all down: in this digital age, pricing too high is akin to waving a red flag at savvy buyers armed...

Thermoplastic Polyimide: A $0.86 Billion Market by 2032

It's not often you get hyped about a compound with a name like 'thermoplastic polyimide,' but hold your horses—this isn't just any chemical. If you're watching markets with a sharp eye, you’ll see this thing estimated at $0.56 billion in 2026, gunning for a hefty $0.86 billion by 2032. We're talking about a solid 7.4% CAGR ride here folks, according to new data from...

DNOW Faces Class Action: Proxy Missteps Under Fire

DNOW's Rough Patch: Investors, Beware Here's a tangled mess for you: DNOW Inc., a name that should've been cruising post-merger, now finds itself smack in the middle of a class action lawsuit. Blame it on some botched acquisition moves with MRC Global Inc. The suits claim DNOW's management may have played fast and loose with the truth during their big merger spiel. When...